A tyrosinase antigen peptide
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

[Asp371]-Tyrosinase (369-377) (human) (trifluoroacetate salt)

Item No. 40152

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(2S,5S,8S,11S,14S,20S)-20-((S)-2-((S)-2-amino-3-(4-hydroxyphenyl)propanamido)-4-(methylthio)butanamido)-5-(3-amino-3-oxopropyl)-14-((R)-1-hydroxyethyl)-8-(hydroxymethyl)-2-isopropyl-11-(2-(methylthio)ethyl)-4,7,10,13,16,19-hexaoxo-3,6,9,12,15,18-hexaazadocosanedioic acid, trifluoroacetate salt
Synonyms
  • [Asp370]-Tyrosinase (368-376)
  • Tyr-Met-Asp-Gly-Thr-Met-Ser-Gln-Val
Molecular Formula
C42H66N10O16S2 • XCF3COOH
Formula Weight
1031.2
Purity
≥98% (mixture of isomers)
Formulation (Request formulation change)
A solid
Peptide Sequence
YMDGTMSQV-OH
Solubility(Learn about Variance in Solubility)
Water: Soluble
SMILES
O=C(N[C@H](C(O)=O)C(C)C)[C@H](CCC(N)=O)NC([C@H](CO)NC([C@H](CCSC)NC([C@H]([C@H](O)C)NC(CNC([C@H](CC(O)=O)NC([C@H](CCSC)NC([C@@H](N)CC(C=C1)=CC=C1O)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C42H66N10O16S2.C2HF3O2/c1-20(2)33(42(67)68)52-39(64)25(10-11-30(44)56)47-40(65)29(19-53)50-38(63)27(13-15-70-5)48-41(66)34(21(3)54)51-31(57)18-45-36(61)28(17-32(58)59)49-37(62)26(12-14-69-4)46-35(60)24(43)16-22-6-8-23(55)9-7-22;3-2(4,5)1(6)7/h6-9,20-21,24-29,33-34,53-55H,10-19,43H2,1-5H3,(H2,44,56)(H,45,61)(H,46,60)(H,47,65)(H,48,66)(H,49,62)(H,50,63)(H,51,57)(H,52,64)(H,58,59)(H,67,68);(H,6,7)/t21-,24+,25+,26+,27+,28+,29+,33+,34+;/m1./s1
InChi Key
TWALUFAMCVRLBU-GPCYTBFMSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $28

    Add

    5 mg

    $125

    Add

    10 mg

    $220

    Add

    25 mg

    $482

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    [Asp371]-Tyrosinase (369-377) is a naturally occurring tyrosinase antigen peptide.1 It is formed via post-translational modification of Asn371.2 [Asp371]-Tyrosinase (369-377) binds to MHC class I subtype HLA-A*0201-positive T2 cells (IC50 = 1.2 µg/ml) and induces lysis of HLA-A2.1-positive T2 cells incubated with cytotoxic T lymphocytes in a concentration-dependent manner.3,1 Immunization with [Asp371]-tyrosinase (369-377)-pulsed, CD40L-activated autologous dendritic cells delays tumor growth in an AAD-expressing B16-F1 melanoma model using transgenic mice expressing HLA-A*0201 linked to the CD8-binding domain of H-2Dd (AAD).4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Skipper, J.C.H., R.C., Gulden, P.H., Brichard, V., et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 83(2), 527-534 (1996).

    2. Mosse, C.A., Meadows, L., Luckey, C.J., et al. The class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosol. J. Exp. Med. 87(1), 37-48 (1998).

    3. van Elsas, A., van der Burg, S.H., van der Minne, C.E., et al. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. Eur. J. Immunol. 26(8), 1683-1689 (1996).

    4. Mullis, D.W., Bullock, T.N.J., Colella, T.A., et al. Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice. J. Immunol. 67(9), 4853-4860 (2001).